General Proximity - About the company
General Proximity is a seed company based in San Francisco (United States), founded in 2023 by Armand B Cognetta III. It operates as a Developer of next generation of induced-proximity medicines. General Proximity has raised $16M in funding. The company has 2604 active competitors, including 888 funded and 621 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Tango Therapeutics and Elicio.
Company Details
Developer of next generation of induced-proximity medicines. The company uses the OmniTAC drug discovery engine which yields molecules that co-opt existing cellular machinery to overcome exigent therapeutic challenges for oncology indications.
- Website
- www.generalproximity.bio/
- Email ID
- *****@generalproximity.bio
Key Metrics
Founded Year
2023
Location
San Francisco, United States
Stage
Seed
Total Funding
$16M in 2 rounds
Latest Funding Round
Investors
Ranked
317th among 2604 active competitors
Employee Count
25 as on Sep 30, 2026
Sign up to download General Proximity's company profile
General Proximity's funding and investors
General Proximity has raised a total funding of $16M over 2 rounds. Its first funding round was on Jan 04, 2025. Its latest funding round was a Seed round on May 04, 2026 for $*****. 1 investor participated in its latest round. General Proximity has 9 institutional investors and 5 angel investors.
Here is the list of recent funding rounds of General Proximity:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 04, 2026 | 7260891 | Seed | 8418297 | 2965528 | 8100447 | 3820922 |
Jan 04, 2025 | 7320649 | Seed | 9370392 | 3398339 | 3040200 |
View details of General Proximity's funding rounds and investors
General Proximity's founders and board of directors
Founder? Claim ProfileThe founders of General Proximity is Armand B Cognetta III. Armand B Cognetta III is the CEO of General Proximity.
Here are the details of General Proximity's key team members:
- Armand B Cognetta III: Founder & CEO of General Proximity. Contact Info: 1 email address
View details of General Proximity's Founder profiles and Board Members
General Proximity's employee count trend
General Proximity has 25 employees as of Sep 26. Here is General Proximity's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
General Proximity's Competitors and alternates
Top competitors of General Proximity include Jazz Pharmaceuticals, Tango Therapeutics and Elicio. Here is the list of Top 10 competitors of General Proximity, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd | Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 72/100 | |
3rd | Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 72/100 | |
4th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
5th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 71/100 | ||
6th | Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
7th | Deciphera 2003, Waltham (United States), Acquired | Developer of type 2 kinase inhibitors for treating cancer | $173M | 70/100 | |
8th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 70/100 | |
9th | Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 69/100 | |
10th | Halozyme 1999, San Diego (United States), Public | Developer of drug delivery technologies for the treatment of various diseases | - | 69/100 | |
317th | General Proximity 2023, San Francisco (United States), Seed | Developer of next generation of induced-proximity medicines | $16M | 53/100 |
Looking for more details on General Proximity's competitors? Click here to see the top ones
General Proximity's Investments and acquisitions
General Proximity has made no investments or acquisitions yet.
Reports related to General Proximity
Here is the latest report on General Proximity's sector:
News related to General Proximity
Media has covered General Proximity for 1 event in last 1 year.
•
•
General Proximity De-Stealths with $16M to Pioneer Next-Gen Induced Proximity Medicines for 'Undruggable' TargetsPR Newswire•Jan 03, 2025•General Proximity, Y Combinator, age1, Modi Ventures
Are you a Founder ?
FAQs about General Proximity
Explore our recently published companies
- TransportHub - Mumbai based, 2016 founded, Early Stage company
- Better Aid BD - Dhaka based, 2021 founded, Unfunded company
- Mold-Tek - Hyderabad based, 1985 founded, Public company
- Questin - Jaipur based, 2026 founded, Unfunded company
- MealSync - Unfunded company
- Provimedia - Bietigheim Bissingen based, 2007 founded, Unfunded company
